Turtle Cameron
SEC CIK 1758363 · EDGAR
BoughtSold
Companies
| Ticker | Company | Title | Holding | Bought | Sold | Trades | First | Last |
|---|---|---|---|---|---|---|---|---|
| SYRE | Spyre Therapeutics, Inc. | CEO, Dir | 552.5K | — | $9.99M | 13 | 2023-11-24 | 2026-09-01 |
Most active insiders at SYRE, 12 months
| # | Insider | Title | Bought | Sold |
|---|---|---|---|---|
| 1 | Fairmount Funds Management LLC | Dir | — | $399.66M |
| 2 | Turtle Cameron | CEO, Dir | — | $9.99M |
| 3 | HENDERSON MICHAEL THOMAS | Dir | — | $7.95M |
| 4 | Sloan Sheldon | Chief Medical Off | — | $7.35M |
| 5 | Burrows Scott L | CFO | — | $6.86M |
| 6 | King-Jones Heidy | See Remarks | — | $2.48M |
| 7 | Albers Jeffrey W. | Dir | — | $2.40M |
Transactions 13
| X | Filed | Traded | Ticker | Company | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| MT | 2026-09-03 21:33 | 2026-09-01 | SYRE | Spyre Therapeutics, Inc. | Turtle Cameron | CEO, Dir | S - Sale | $87.29 | -15.0K | 552.5K | -3% | -$1.31M |
| MT | 2026-08-05 21:31 | 2026-08-03 | SYRE | Spyre Therapeutics, Inc. | Turtle Cameron | CEO, Dir | S - Sale | $95.51 | -15.0K | 567.5K | -3% | -$1.43M |
| MT | 2026-07-02 21:32 | 2026-07-01 | SYRE | Spyre Therapeutics, Inc. | Turtle Cameron | CEO, Dir | S - Sale | $87.69 | -15.0K | 582.5K | -3% | -$1.32M |
| MT | 2026-06-03 21:31 | 2026-06-01 | SYRE | Spyre Therapeutics, Inc. | Turtle Cameron | CEO, Dir | S - Sale | $70.43 | -15.0K | 597.5K | -2% | -$1.06M |
| MT | 2026-05-01 21:34 | 2026-05-01 | SYRE | Spyre Therapeutics, Inc. | Turtle Cameron | CEO, Dir | S - Sale | $71.37 | -15.0K | 612.5K | -2% | -$1.07M |
| MT | 2026-04-03 21:30 | 2026-04-01 | SYRE | Spyre Therapeutics, Inc. | Turtle Cameron | CEO, Dir | S - Sale | $49.33 | -15.0K | 627.5K | -2% | -$739.9K |
| M | 2026-03-03 | 2026-03-02 | SYRE | Spyre Therapeutics, Inc. | Turtle Cameron | CEO, Dir | S - Sale | $42.19 | -15.0K | 651.6K | -2% | -$632.9K |
| M | 2026-02-04 | 2026-02-02 | SYRE | Spyre Therapeutics, Inc. | Turtle Cameron | CEO, Dir | S - Sale | $32.80 | -15.0K | 657.5K | -2% | -$492.0K |
| M | 2026-01-06 | 2026-01-02 | SYRE | Spyre Therapeutics, Inc. | Turtle Cameron | CEO, Dir | S - Sale | $30.68 | -15.0K | 672.0K | -2% | -$460.1K |
| M | 2025-12-03 | 2025-12-01 | SYRE | Spyre Therapeutics, Inc. | Turtle Cameron | CEO, Dir | S - Sale | $29.02 | -15.0K | 690.9K | -2% | -$435.4K |
| M | 2025-11-05 | 2025-11-03 | SYRE | Spyre Therapeutics, Inc. | Turtle Cameron | CEO, Dir | S - Sale | $23.33 | -45.0K | 701.9K | -6% | -$1.05M |
| 2024-02-20 | 2024-02-15 | SYRE | Spyre Therapeutics, Inc. | Turtle Cameron | CEO, Dir | A - Grant | $9.82 | +400 | 746.9K | +0.1% | +$3,928 | |
| D | 2023-11-27 | 2023-11-24 | SYRE | Spyre Therapeutics, Inc. | Turtle Cameron | CEO, Dir | C - Cnv Deriv | $0.00 | +723.4K | 746.5K | +3,136% | $0 |
Purchase Sale Sale after option exercise All abbreviations